Trials / Conditions / Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

21 registered clinical trials studyying Severe Hypertriglyceridemia — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia NCT07269210	Eli Lilly and Company	Phase 2
Recruiting	Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis NCT06880770	Arrowhead Pharmaceuticals	Phase 3
Completed	A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemi NCT06555640	Zhejiang Doer Biologics Co., Ltd.	Phase 2
Active Not Recruiting	Study of Plozasiran in Adults With Severe Hypertriglyceridemia NCT06347016	Arrowhead Pharmaceuticals	Phase 3
Active Not Recruiting	Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia NCT06347003	Arrowhead Pharmaceuticals	Phase 3
Active Not Recruiting	To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia NCT05852431	89bio, Inc.	Phase 3
Active Not Recruiting	CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertrig NCT05681351	Ionis Pharmaceuticals, Inc.	Phase 3
Completed	A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia NCT05552326	Ionis Pharmaceuticals, Inc.	Phase 3
Completed	A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atheroscler NCT05355402	Ionis Pharmaceuticals, Inc.	Phase 2
Completed	A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia NCT05079919	Ionis Pharmaceuticals, Inc.	Phase 3
Withdrawn	Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg NCT04662528	Matinas Biopharma, Inc	Phase 3
Completed	Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia NCT04720534	Arrowhead Pharmaceuticals	Phase 2
Completed	Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyce NCT04541186	89bio, Inc.	Phase 2
Completed	A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertrigl NCT02944383	NeuroBo Pharmaceuticals Inc.	Phase 2
Completed	Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and NCT03001817	Kowa Research Institute, Inc.	Phase 3
Completed	Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and NCT03011450	Kowa Research Institute, Inc.	Phase 3
Completed	An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lov NCT02189252	AstraZeneca	Phase 1
Completed	Epanova® for Lowering Very High Triglycerides NCT01242527	AstraZeneca	Phase 2 / Phase 3
Unknown	Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia NCT01229566	Trygg Pharma, Inc.	Phase 3
Completed	Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation NCT01208961	AstraZeneca	Phase 2
Withdrawn	The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL) NCT01997268	Sancilio and Company, Inc.	Phase 3